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(57) ABSTRACT 
The presently-disclosed subject matter includes methods 
and devices for diagnosing, prognosing, and treating brain 
damage in a subject, including brain damage caused by 
stroke or a traumatic brain injury (TBI). The methods can 
comprise providing a sample obtained from the subject, 
exposing the sample to an antibody selective for a visinin-
like protein, detecting the presence of a complex that 
includes the antibody and the visinin-like protein, and diag-
nosing and/or prognosing the subject as having brain dam-
age if there is the presence of the complex. Embodied 
methods can also comprise administering a treatment for 
brain damage if the subject includes the presence of the 
visinin-like protein. 
33 Claims, 7 Drawing Sheets 
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METHODS AND SYSTEMS FOR PROGNOSIS 
AND DIAGNOSIS OF BRAIN DAMAGE 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Patent Application No. 61/860,645, filed Jul. 31, 2013, the 
entire disclosure of which is incorporated herein by this 
reference. 
2 
TECHNICAL FIELD 
that lasts more than 24 hours, and generally demonstrate 
GCS scores of 14 or 15. Therefore, mild TBI is difficult to 
diagnose because mild TBI can present limited injury and 
only subtle changes in GCS scores. Patients with moderate 
TBI generally have a loss of consciousness that lasts greater 
than 30 minutes, have post injury anmesia, and generally 
demonstrate GCS scores of 9 to 12. On the other hand, 
patients with severe TBI, which typically include victims of 
poly-trauma, are relatively easier to diagnose when com-
10 pared to patients having mild and moderate injuries. 
Because of difficulties associated with clinical diagnosis 
of mild and moderate TBI and stroke, others have attempted 
to develop biochemical and surrogate markers of TBI that The presently-disclosed subject matter relates to methods 
and systems for prognosis, diagnosis, and treatment of brain 
damage in a subject. In particular, the presently-disclosed 
subject matter relates to methods and systems for prognos-
ing, diagnosing, and treating brain damage that include 
measuring levels ofvisinin-like family proteins in a biologi-
cal sample obtained from a subject. 
15 can be measured in circulating fluids, diagnose the extent of 
injury, and define the anatomical and cellular pathology 
associated with injury. Current biomarkers of TBI are clas-
sified by their pathophysiological role and include molecules 
involved in neuroinflmation, glial activation, neuron dys-
20 function/degeneration, and markers of oxidative stress. 
INTRODUCTION 
Traumatic brain injury (TBI) is a significant civilian and 
military hearth concern. Brain injury can exist in individuals 
who experience concussive or sub-concussive blows to the 25 
head, and has particular relevance to athletic and military 
activities. Without reliable diagnostics that can determine 
whether a blow to the head affected the brain, athletes and 
soldiers can return to their sport or to combat and be exposed 
Known biomarkers include creatine kinase (CK), glial fibril-
lary protein (GFAP), lactate dehydrogenase (LDH), myelin 
basic protein (MBP), neuron specific enolase (NSE), S100~, 
and markers of neuroinflammation. 
However, known biomarker have limited capabilities For 
instance, even though known biomarkers may identifY sub-
jects having experienced a stroke from normal subjects, 
known biomarkers are not capable of delineating between 
ischemic stroke patients and patients having experienced a 
to additional injuries which may be associated with chronic 
and progressive symptoms and neuropathologic damage. 
Similarly, about 795,000 Americans suffer a stroke each 
year, and stoke is a leading cause of serious long-term 
disability. Ischemic strokes, due to blocked blood vessels in 
the brain, account for about 87% of all strokes. 
30 hemorrhagic stroke, seizure, migraine, syncope, hypoglyce-
mia, and the like. Furthermore, although some biomarkers 
have been identified as potentially being useful for charac-
terizing brain damage, most known biomarkers are quanti-
fied using time-consuming techniques, such as enzyme 
Current diagnostic and prognostic tools used for evalua-
tion ofTBI and stroke remain limited particularly for in field 
(i.e., pre-hospital) evaluation. Central to the clinical diag-
nosis ofTBI is the use of non-contrast computer tomography 
(CT) and magnetic resonance imaging (MRI). Non-contrast 
CT is generally the initial test for diagnosis of TBI because 
of its availability at most healthcare facilities. Although CT 
35 linked immunoassays (ELISAs) that can take as long as 24 
hours to complete. Therefore, known techniques provide 
limited information on a subject only after an optimal time 
period for treatment has passed. 
Hence, there remains a need for a biomarker that can be 
40 used for the diagnosis and prognosis of brain damage. There 
also remains a need for systems that can be used to identifY 
and measure biomarkers in a sample collected from a subject 
within a clinically relevant time period. is sensitive in the identification of acute hemorrhage and 
fracture associated with severe injury, it is relatively insen-
sitive in the identification of diffuse injury associated with 45 
milder TBI. Also, CT scans often appear to be normal after 
the onset of an ischemic stroke and may remain normal for 
hours after the event. MRI is capable of detecting hemato-
mas, small contusions, and ischemic events not captured by 
CT, but it is relatively insensitive to diffuse axonal injury and 50 
may not be feasible in all situations. 
Furthermore, the time delay associated with current diag-
nostic approaches for stroke patients limits the time during 
which thrombolytics (tissue plasminogen activator; t-PA) 
may be administered. Administration oft-PA improves neu- 55 
rologic outcomes in patients with ischemic stroke, but the 
therapeutic window can be less than 6 hours after the event 
and can be as few as 2 or 3 hours post ischemia. Because of 
the potential detrimental effects of use oft-PA in patients 
with a small hemorrhagic stroke, the lack of a diagnostic that 60 
can quickly differentiate between hemorrhagic and ischemic 
stroke is associated with underuse of fibrinolytic treatment. 
Determination of the Glasgow Coma Scale (GCS) is also 
used to diagnose the degree of brain injury. Patients with 
mild TBI generally have no penetrating injuries of the head 65 
or other organs, experience less than 30 minutes of lost or 
altered consciousness, may demonstrate post-injury anmesia 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the presently-disclosed subject 
matter are set forth with particularity in the appended claims. 
A better understanding of the features and advantages of the 
presently-disclosed subject matter will be obtained by ref-
erence to the following detailed description that sets forth 
illustrative embodiments, in which the principles of the 
invention are used, and the accompanying drawings of 
which: 
FIG. 1 includes a schematic showing an embodiment of a 
lateral flow device (LFD) comprising a laminate backing 
(A), a detection portion (B), a wicking portion (C), a 
conjugate portion (D), and a sample portion (E), wherein a 
VILIP-1 K-25 antibody is deposited as a stripe left of 'B', 
Goat Serum is deposited as a stripe right of 'B', and 
conjugate that includes nanogold beads labeled with 
VILIP-1 PL-A2 is illustrated as a shaded area on 'D'. 
FIG. 2 includes images showing VILIP-1 levels in normal 
control serum measured using a lateral flow device. 
FIG. 3 includes images showing VILIP-1 levels for isch-
emic stroke, mild traumatic brain injury (TBI), and moderate 
TBI samples from animal subjects. 
US 9,482,675 Bl 
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FIG. 4 includes a plot showing mean±standard error of the 
mean (SEM) VILIP-1 levels in rats subjected to an ischemic 
event induced by suture occlusion of the middle cerebral 
artery pre-injury, at the end of the 1 hour of occlusion, 15 
minutes after the initiation of reperfusion, and 24 hours post 
reperfusion. 
FIG. 5 includes a plot showing receiver operating char-
acteristic (ROC) curves for VILIP-1 levels in serum samples 
from rats subjected to middle cerebral artery occlusion as a 
model of ischemic stroke. 
FIG. 6 shows mean±SEM VILIP-1 levels in serum from 
surgery naive rats or rats subjected to mild or moderate TBI 
that were taken 1, 3, and 4 hours post injury. 
FIG. 7 includes a chart showing receiver operating char-
acteristic (ROC) curves for VILIP-1 levels in serum samples 
from rats that were taken 1, 3, and 4 hours following mild 
or moderate TBI. 
FIG. 8 includes a chart showing VILIP-1 levels in serum 
from two subjects with hemorrhagic stroke and two subjects 
with ischemic stroke. 
FIG. 9 includes a chart showing VILIP-1 levels relative to 
infarct volume for two subjects with hemorrhagic stroke and 
two subjects with ischemic stroke. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
The presently-disclosed subject matter relates to methods 
and systems for diagnosing, prognosing, and/or treating 
brain damage, including brain damage caused by a stroke 
and/or a traumatic brain injury (TBI). The present inventors 
have identified biomarkers that can effectively diagnose and 
prognose such brain damage. In some instances, the bio-
markers of TBI or stroke be based on substrates that are 
relevant and/or specific to the central nervous system and 
should provide information about injury mechanisms. 
In some instances, the biomarkers be measurable in 
accessible biological fluids, such as cerebrospinal fluid and 
blood, and should correlate with the severity of injury and 
resulting functional deficits. Additionally, exemplary bio-
markers have high sensitivity for identification of subjects 
(i.e., high positive identification), high specificity (i.e., low 
false positive identifications), and have an appearance pro-
file that follows neuronal/glial injury. In this regard, the 
present inventors have found that visinin-like proteins 
(VILIPs) can serve as biomarkers for brain damage. 
Diagnosis and Prognosis 
The presently-disclosed subject includes methods for 
diagnosing and/or prognosing brain damage in a subject. 
Exemplary methods include providing a biological sample 
obtained from the subject, and subsequently determining a 
presence of a visinin-like protein in the sample obtained 
from the subject, the presence of the visinin-like protein 
indicating that the subject has brain damage. The terms 
"biological sample" and "sample" are used interchangeably 
herein to generally refer to a sample that is intended to be 
4 
subjected to qualitative and/or quantitative measurements to 
determine whether there is an absence, presence, and/or 
particular concentration of a component. In some instances 
the sample includes a circulating fluid, and can include a 
fluid that circulates within the central nervous system. 
Exemplary types of biological samples include serum, 
blood, plasma, cerebrospinal fluid, and the like. The sample 
may or may not include cells from the subject. Depending on 
the type of sample obtained for a particular method, any 
10 suitable known method can be used to obtain the sample 
from the subject. The volume of a sample is also not 
particularly limited, and is about 10 f.LL to about 1,000 mL 
in some of the presently-disclosed embodiments. 
The term "subject" is not particularly limited, and is 
15 inclusive of a vertebrates, such as mammals. The term 
"subject" includes human and veterinary subjects. Thus, the 
subject of the herein disclosed methods can be a human, 
non-human primate, horse, pig, rabbit, dog, sheep, goat, 
cow, cat, guinea pig, rodent, or the like. The term does not 
20 denote a particular age or sex. Thus, adult and newborn 
subjects, as well as fetuses, whether male or female, are 
intended to be covered. 
The terms "diagnosing," "diagnosis," and the like as used 
herein refer to methods by which the skilled artisan can 
25 estimate and even determine whether or not a subject is 
suffering from a given disease or condition. Along with 
diagnosis, "prognosis," "prognosing," and the like are also 
an area of great concern and interest, and can refer to 
predicting a clinical outcome (with or without medical 
30 treatment), selecting an appropriate treatment (or whether 
treatment would be effective), or monitoring a current treat-
ment and potentially changing the treatment, based on the 
presence of a visinin-like protein. The terms "diagnose" and 
"prognosis" can refer to the ability to determine or predict 
35 the course or outcome of a condition with up to 100% 
accuracy, or predict that a given course or outcome is more 
or less likely to occur. In certain embodiments, a diagnosis 
or prognosis is indicative of an about 10%, about 20%, about 
30%, about 40%, about 50%, about 60%, about 70%, about 
40 80%, or about 90% chance that the subject has brain 
damage. If an accurate diagnosis and/or prognosis can be 
made, appropriate therapy, and in some instances less severe 
therapy or more effective therapy, for the subject can be 
chosen. In some embodiments of the presently-disclosed 
45 subject matter, a method includes identifying a subject as 
having brain damage, possible due to TBI or a stroke, if a 
sample obtained from the subject includes a presence of a 
visinin-like protein. 
In the various methods and system described herein, the 
50 visinin-like protein can be selected from the group consist-
ing of VILIP-1, VILIP-2, VILIP-3, hippocalcin, neurocalin 
delta, and combinations thereof. The terms "polypeptide", 
"protein", and "peptide", which are used interchangeably 
herein, refer to a polymer of the protein amino acids 
55 regardless of its size or function. The terms "protein", 
"polypeptide", and "peptide" are used interchangeably 
herein to also refer to a gene product, homologs, orthologs, 
paralogs, fragments, any protease derived peptide (frag-
ment), and other equivalents, variants, and analogs of a 
60 polymer of amino acids. 
In general, calcium balance is maintained in the central 
nervous system by either Ca buffering or Ca sensing pro-
teins. As mentioned above, the visinin-like protein family 
represents a specific subfamily of brain associated Ca2 +-
65 sensors that include VILIP-1, VILIP-2, VILIP-3, hippocal-
cin, and neurocalin delta. These proteins possess 4 EF -hand 
Ca2+-binding moieties that, upon Ca2 + binding, lead to 
US 9,482,675 Bl 
5 
regulation of cyclic nucleotide levels, modulation of voltage 
gated Ca2 + and A type K+ channels, transcriptional repres-
sion, kinase modulation, and neurotransmitter release. 
For example, VILIP-1 in neurons undergoes a Ca2 +-
dependent association with the plasma membrane or Golgi 
membranes and has modulatory effects on signaling of 
cAMP and cGMP. In addition, VILIP-1 modulates activity 
of guanyl cyclase B through clathrin-dependent receptor 
cycling and plays a role in regulation of gene expression by 
binding double stranded RNA. In human brain, VILIP-1 10 
protein has been demonstrated in the prefrontal, cingulate, 
insular and temporal cortices, putamen, nucleus accumbens 
but not caudate. In the hippocampus, VILIP-1 is present in 
a subset of pyramidal neurons in CAl and CA4 but is not 15 
observed in CA2 or CA3. Immunostaining of VILIP-1 in 
amygdala and hypothalamus is considerably weaker than in 
hippocampus, whereas intense staining is observed in the 
cerebellum and in vestibular and trigeminal neurons of the 
brainstem. VILIP-1 in a rat model of ischemic stroke can be 20 
elevated at both the mRNA and protein levels at 24 hour 
post-injury. 
The step of determining the presence of a visinin-like 
protein is also not particularly limited. In some embodi-
ments the presence of a visinin-like protein can be deter- 25 
mined via an enzyme-linked immunosorbent assay (ELISA). 
In other embodiments the detecting step is performed via a 
novel lateral flow device that comprises one or more anti-
bodies that are specific for the visinin-like protein, as 
described further below. Thus, the determining step can 30 
include detecting a measurable presence of a visinin-like 
protein in a substance. 
In some embodiments the presence of a visinin-like 
protein is established if it is determined that the sample 
includes any measurable amount of the visinin-like protein. 35 
In other embodiments the presence of a visinin-like protein 
is established only if the visinin-like protein is present at a 
particular concentration and/or range of concentrations. In 
some embodiments the presence of a visinin-like protein is 
established if the visinin-like protein is present at concen- 40 
tration of 100 ng/ml or more, 200 ng/ml or more, 300 ng/ml 
or more, 400 ng/ml or more, 500 ng/ml or more, 600 ng/ml 
or more, 700 ng/ml or more, 800 ng/ml or more, 900 ng/ml 
or more, 1,000 ng/ml or more, 2,000 ng/ml or more, 3,000 
ng/ml or more, 4,000 ng/ml or more, 5,000 ng/ml or more, 45 
6,000 ng/ml or more, 7,000 ng/ml or more, 8,000 ng/ml or 
more, 9,000 ng/ml or more, or 10,000 ng/ml or more. In yet 
other embodiments, as described herein, the concentration of 
6 
In this regard, embodiments of the present methods can be 
used to determine the severity of brain damage, and option-
ally can determine the severity of the brain damage as a 
function of time. For example, embodiments may be able to 
categorize a TBI as being mild, moderate, or severe based on 
the concentration of a visinin-like protein in a sample. Thus, 
in some embodiments the present methods are performed on 
a subject known or suspected as having a TBI, and in some 
embodiments is performed about 1 minute to about 24 hours 
after an event that caused or is suspected of having caused 
TBI. In some embodiments, a concentration of at least about 
200 ng/ml of a visinin-like protein (e.g., VILIP-1) in a 
sample obtained from a subject one hour post injury indi-
cates that the subject has experienced mild TBI, and for 
some subjects a concentration of at least about 500 ng/ml of 
the visinin-like protein-! one hour post injury indicates that 
the subject has experienced moderate TBI. In some embodi-
ments where a sample is obtained from a subject three hours 
post injury, a concentration of about 200 ng/ml to about 800 
ng/ml of a visinin-like protein in the sample indicates that 
the subject experienced a mild TBI, and in other embodi-
ments a concentration of about 800 ng/ml or more of a 
visinin-like protein in the sample indicates that the subject 
experienced moderate TBI. 
Other embodiments of the present methods can categorize 
a stroke as being either ischemic or hemorrhagic and/or can 
categorize the stroke as being mild, moderate, or severe 
based on concentration of a visinin-like protein present in a 
sample. In some embodiments a subject can be diagnosed 
has having experienced an ischemic stroke if the subject 
exhibits a presence of a visinin-like protein at a concentra-
tion that is below a concentration of visinin-like protein 
expressed in subjects with TBI, including mild TBI, and 
hemorrhagic stroke. On the other hand, in some embodi-
ments a subject can be diagnosed has having experienced an 
hemorrhagic stroke if the subject exhibits a presence of a 
visinin-like protein at a concentration that is approximately 
equal to or above a concentration of visinin-like protein 
expressed in subjects with mild TBI. 
In specific embodiments the presence of the visinin-like 
protein at a concentration of about 100 ng/ml to a concen-
tration of about 400 ng/ml in the sample is indicative of 
ischemic stroke, whereas the presence of the visinin-like 
protein in excess of about 700 ng/ml in the sample is 
indicative hemorrhagic stroke. In some embodiments the 
present methods are performed on subjects known or sus-
pected to have experienced a stroke. In yet other specific 
embodiments, wherein the subject is a human known or 
suspected of having experienced a stroke, a presence of the a visinin-like protein can indicate the disease or condition 
that has or is causing brain damage in a subject. 50 visinin-like protein below about 5,000 ng/ml in a sample 
obtained from the subject is indicative of ischemic stroke, 
and a presence of the visinin-like protein above about 5,000 
ng/ml in a sample obtained from the subject is indicative of 
For example, the present methods for diagnosing and/or 
prognosing may be used for any brain damage. Types of 
brain damage that can be diagnosed and/or prognosed with 
the present methods include, but is not limited to, brain 
damage caused by a traumatic brain injury (TBI), including 55 
mild, moderate, or severe TBI, a stroke, including hemor-
rhagic stroke or ischemic stroke, a seizure, a migraine, a 
syncope, and the like. In some embodiments the brain 
damage can include brain damage due to neuronal damage, 
hypoxic damage, or both. Thus, the present methods can 60 
provide a relatively simple and noninvasive way to identify 
brain damage caused by a wide range of diseases, condi-
tions, and events for a variety of subjects. In some embodi-
ments the subject includes a premature infant, and the brain 
damage being diagnosed, prognosed, and/or treated can 65 
include neuronal damage, hypoxic damage, and combina-
tions thereof. 
hemorrhagic stroke. In some instances the methods are 
performed about 1 minute to about 24 hours after the known 
or suspected stroke in order to provide a clinically relevant 
diagnosis and/or prognosis. 
Additionally, embodiments of the methods and systems 
described herein can diagnose and/or prognose a subject 
with brain damage and/or a particular type of brain damage 
relatively quickly by determining the presence of a visinin-
like protein in a sample collected from a subject. The 
relatively rapid diagnosis and/or prognosis can permit rel-
evant treatments to be administered to a subject in need soon 
after the occurrence of brain damage, potentially increasing 
the effectiveness of the administered treatment. For 
example, in the case of subjects believed to have potentially 
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have suffered a stroke, it can be beneficial to delineate 
whether the subject has had an ischemic stroke or a hem-
orrhagic stroke as soon as possible, and in some instances 
within two hours of the event believed to have been a stroke. 
Generally, outcomes are superior if treatment can be admin-
istered for an ischemic stroke within this early time frame. 
Generally, treatment for ischemic stroke (e.g., thrombolytic 
treatment) cannot be administered until one is diagnosed 
with ischemic stroke, particularly if there is a risk that the 
subject might otherwise have a TBI or hemorrhagic stroke. 10 
methods can comprise a step of providing a biological 
sample obtained from the subject, a step of determining a 
presence of a visinin-like protein in the subject, wherein the 
presence of the visinin-like protein indicates that the subject 
has brain damage, and a step of administering a treatment for 
brain damage if the subject includes the presence of the 
visinin-like protein. Accordingly, some embodiments can 
comprise a step of treating brain damage if the subject is 
diagnosed and/or prognosed as having brain damage. 
The terms "treatment" or "treating" refer to the medical 
In some embodiments a determination regarding the pres-
ence of a visinin-like protein can be made in about 15 
minutes or less following obtaining a sample. Regardless of 
the time required to make such a determination, embodi-
ments of the presently-disclosed methods can provide a 
diagnosis and/or prognosis in less than about 24 hours, in 
less than about 6 hours, in less than about 4 hours, in less 
than about 3 hours, in less than about 2 hours, and in less 
than about 1 hour following obtaining a sample. In specific 
embodiments, the present methods and systems can provide 
a diagnosis and/or prognosis within about 1 to about 30 
minutes, or within about 1 to about 15 minutes. This 
characteristic of embodied methods can be beneficial 
because visinin-like protein levels can be altered in blood as 
soon as 1 hour following TBI or ischemic stroke. 
In certain embodiments of the presently-disclosed subject 
matter, a method for diagnosing and/or prognosing brain 
damage in a subject is provided, wherein the method com-
prises providing a biological sample obtained from the 
subject, exposing the sample to an antibody that is selective 
for a visinin-like protein, detecting the presence of a com-
plex that includes the antibody and the visinin-like protein, 
and diagnosing and/or prognosing the subject as having 
brain damage if there is a presence of the complex. The 
terms "selective for," "selectivity," and the like are used 
herein to refer to a characteristic of a molecule that prefer-
entially and/or exclusively binds a target molecule. Selec-
tivity can be imparted by the charge, conformation, and/or 
functional groups of the selective molecule. It will be 
understood that certain antibodies can selectively bind to 
target proteins. 
Alternatively or additionally, in some embodiments the 
antibody utilized in the present methods is provided as a 
conjugate that includes the antibody that is selective for the 
visinin-like protein and a detection probe. Subsequently, the 
detecting step includes detecting the presence of a complex 
that includes the visinin-like protein and the conjugate, 
which itself includes the antibody conjugated to the detec-
tion probe. Detection probes may be selected from those 
known in the art, including fluorescent compounds, radio-
active compounds, nanobeads, visual labels, or combina-
tions thereof. In some embodiments the nanobeads are 
nanogold beads. 
In other embodiments of the present methods for the 
diagnosis and/or prognosis of brain damage in a subject, the 
methods can comprise providing a biological sample 
obtained from the subject, determining a presence of two or 
more visinin-like proteins in the subject, and diagnosing 
and/or prognosing the subject as having brain damage if 
there is the presence of the two or more visinin -like proteins. 
The two or more visinin-like proteins can be selected from 
VILIP-1, VILIP-2, VILIP-3, hippocalcin, neurocalin delta, 
and combinations thereof. In some embodiments at least one 
of the two or more visinin-like proteins includes VILIP-1. 
Treatment 
The presently-disclosed subject matter also provides 
methods for treating brain damage in a subject. Exemplary 
management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or 
disorder. This term includes active treatment, that is, treat-
ment directed specifically toward the improvement of a 
15 disease, pathological condition, or disorder, and also 
includes causal treatment, that is, treatment directed toward 
removal of the cause of the associated disease, pathological 
condition, or disorder. In addition, this term includes pal-
liative treatment, that is, treatment designed for the relief of 
20 symptoms rather than the curing of the disease, pathological 
condition, or disorder; preventative treatment, that is, treat-
ment directed to minimizing or partially or completely 
inhibiting the development of the associated disease, patho-
logical condition, or disorder; and supportive treatment, that 
25 is, treatment employed to supplement another therapy 
directed toward the improvement of the associated disease, 
pathological condition, or disorder. 
The term "administering" is not particularly limited, and 
refers to any method of providing a composition and/or 
30 pharmaceutical composition thereof to a subject. Such meth-
ods are well known to those skilled in the art and include, but 
are not limited to, oral administration, transdermal admin-
istration, administration by inhalation, nasal administration, 
topical administration, intravaginal administration, ophthal-
35 mic administration, intraaural administration, intracerebral 
administration, rectal administration, and parenteral admin-
istration, including injectable such as intravenous adminis-
tration, intra-arterial administration, intramuscular adminis-
tration, subcutaneous administration, intravitreous 
40 administration, intracameral (into anterior chamber) admin-
istration, subretinal administration, sub-Tenon's administra-
tion, peribulbar administration, administration via topical 
eye drops, and the like. Administration can be continuous or 
intermittent. In various aspects, a preparation can be admin-
45 istered therapeutically; that is, administered to treat an 
existing disease or condition. In further various aspects, a 
preparation can be administered prophylactically; that is, 
administered for prevention of a disease or condition. 
In some embodiments the subject is diagnosed and/or 
50 prognosed with a certain type of brain damage so that an 
appropriate treatment can be administered. For example, 
some embodiments of the present treatment methods com-
prise administering to the subject a treatment for TBI, 
hemorrhagic stroke, or ischemic stroke if the subject is 
55 diagnosed with, respectively, TBI, hemorrhagic stroke, or 
ischemic stroke. In some embodiments the treatment for 
ischemic stroke can include a thrombolytic therapy. The 
thrombolytic therapy can include administration of com-
pounds selected from the group consisting of warfarin, 
60 aspirin, and thrombolytic drugs such as tissue plasminogen 
activators (e.g., alteplase, reteplase, tenecteplase ), anistre-
plase, streptokinase, urokinase, and any other thrombolytic 
therapies known in the art. 
The present treatment method can also comprise steps of 
65 altering treatments depending on the severity of the brain 
damage or the disease, condition, or event that caused the 
brain damage. For instance, in some embodiments the 
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present methods include a step of characterizing the severity 
of an ischemic stroke depending on the concentration of the 
visinin-like protein that is present in the sample provided 
from the subject. Thereafter, the severity of the diagnosed 
ischemic stroke can also be used to direct and optimize 
treatment of the ischemic stroke. 
Device 
The presently-disclosed subject matter provides devices 
for detecting the presence of a visinin-like protein in a 
sample. In some embodiments the device is a lateral flow 
device (LFD). In some embodiments the lateral flow device 
can further comprise a vertical flow device. Exemplary 
devices can be stable at room temperature, and some devices 
can be stored for extended periods for future use. 
10 
within a range of concentrations. The devices can thus detect 
the presence of a visinin-like protein so that the device can 
be utilized to diagnose and/or prognose a subject with brain 
damage or specific sources of brain damage such as TBI or 
a stroke. Some embodiments of the present devices can 
detect the presence of the visinin-like protein in a sample at 
a concentration of at least about 20 ng/ml or more. Some 
embodiments of the present devices can detect the presence 
of the visinin-like protein in a sample at a concentration of 
10 about 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, 500 
ng/ml, 600 ng/ml, 700 ng/ml, 800 ng/ml, 900 ng/ml, 1,000 
ng/ml, 2,000 ng/ml, 3,000 ng/ml, 4,000 ng/ml, 5,000 ng/ml, 
6,000 ng/ml, 7,000 ng/ml, 8,000 ng/ml, 9,000 ng/ml, 10,000 
ng/ml, or more. 
In some embodiments the device includes a sample por-
tion, a conjugate portion, and a detection portion. Option-
ally, in some embodiments a wicking portion is provided 
downstream of the conjugate portion and is intended to 
collect any residual sample that flows through the device and 
In this respect, typically it can take up to 24 hours to 15 
quantifY levels of the protein of interest using ELISAs. This 
relatively long time period is outside potentially therapeutic 
windows for many types of brain damage, including certain 
types of stroke and TBI. On the other hand, the present 
devices include lateral flow devices and vertical/lateral flow 
devices that allow for more rapid quantification of biomark-
20 past the detection portion. The sample portion, conjugate 
portion, detection portion, and wicking portion of embodied 
devices can be comprised of one continuous piece of a 
material or can be comprised of two or more distinct 
materials that may or may not be of the same type as one 
ers (e.g., visinin-like protein) in subjects having or suspected 
of having TBI, stroke, or other brain damage. In general, 
lateral flow devices use material(s) that cham1el analytes 
(i.e., visinin-like proteins) into close proximity with target 
substances, such as antibodies, and can allow reaction and 
binding of the target substance to the analytes. Lateral 
movement of the sample in the lateral flow device allows for 
its controlled interaction with agents (e.g., antibodies) which 
can be located along the test cham1el(s), thereby allowing 
control of sequencing and timing of interactions. 
The present lateral flow devices can employ passive 
means, such as capillary forces, of fluid movement that is not 
aided by a fluid pump. The present lateral flow devices can 
comprise natural or synthetic lateral flow materials. The 
materials can have porous structures that induce capillary 
forces. In some embodiments the lateral flow devices com-
prise capillary tubes or channels to direct flow. Exemplary 
materials for the devices include, but are not limited to, 
polysaccharides (e.g., cellulose materials such as paper and 
cellulose derivatives, such as cellulose acetate and nitrocel-
lulose), polyether sulfone, polyethylene, nylon, polyvi-
nylidene fluoride (PVDF), polyester, terephthalate (polyes-
ter) (PET), polymethylmethacrylate (PMMA), polystyrene, 
polypropylene, silica, inorganic materials, such as deacti-
vated alumina, glass, diatomaceous earth, MgS04 , ceramics, 
or other inorganic finely divided material uniformly dis-
persed in a porous polymer matrix, natural and/or synthetic 
cloth (e.g., cotton, nylon, or rayon), porous gels, such as 
silica gel, agarose, dextran, and gelatin, polymeric films, 
such as polyacrylamide; and the like. 
25 another. For example, the detection portion and the wicking 
portion can be formed from one continuous material, 
wherein the detection portion and wicking portion refer to 
different sections the piece of material, and in other embodi-
ments the detection portion and the wicking portion can be 
30 comprised of two distinct materials. 
The sample portion is provided to receive a sample. In 
some embodiments the sample portion can further receive a 
substance that permits the biological sample to cross through 
the device, such as a buffer solution (e.g., PBS). In some 
35 embodiments the biological samples comprise about 10 f.LL 
to about 1000 fll of a liquid sample. 
Exemplary sample portions can further comprise an albu-
min eliminator for removing albumin from the biological 
sample, wherein "albumin eliminator" refers to any material, 
40 substance, or means for removing albumin from a substance. 
When the biological sample is whole blood or serum, 
embodiments of the sample portions can remove cells from 
the biological sample before it progresses to the other 
portions and membranes of the device. The cell and/or 
45 albumin removing means prevent the red blood cells or 
albumin from interfering with the test procedure and can 
help ensure that readings for the presence of a visinin-like 
protein are accurate. For example, red blood cells typically 
constitute about half of the volume of a blood sample. 
50 Unless the red blood cells are substantially removed, their 
presence can affect certain results that are sensitive to color. 
Hemoglobin can also interfere chemically with certain meth-
ods, and is removed by in some embodiments of the present 
methods and devices. 
The devices described herein can provide an efficient, 
accurate, and expedient manner in which to determine the 
presence of a visinin-like protein in a biological sample 
collected from a subject, and then potentially use this 55 
determination to make a diagnosis and/or prognosis within 
In some embodiments plasma is separated from red blood 
cells is by centrifugation prior to applying the sample to a 
device. Other exemplary methods for removing red blood 
cells are described in U.S. Pat. No. 4,477,575, which is 
incorporated herein by reference, and describes a blood filter 
made from glass fiber that can separate out red blood cells 
when whole blood is slowly trickled onto one side. Unsatu-
a clinically relevant time. In some embodiments the present 
devices can provide a diagnosis and/or prognosis within 
about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 
rated aliphatic fatty acid or an ester thereof can also be 
provided in some devices, including on the sample portion 
of some devices, and can induce the formation of red blood 
6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 60 
minutes, 20 minutes, or 30 minutes of applying a sample to 
the device. In some embodiments the present devices can 
provide a diagnosis and/or prognosis in about 1 hour or less, 
about 2 hours or less, about 3 hours or less, about 4 hours or 
less, about 5 hours or less, or about 6 hours or less. 65 cells that are distorted in shape and less flexible and mal-
leable than normal red blood cells, making them less able to 
penetrate and flow through the device. The stiffer, less 
The present devices can be configured to detect a visinin-
like protein in a sample at a minimum concentration or 
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flexible cells cannot move easily and become trapped, while 
the liquid components of the sample can flow through the 
device and penetrate the detection portion for analysis. 
Those of ordinary skill will recognize other means and 
substances for removing red blood cells and other interfering 
substances from a sample that is intended for detecting a 
visinin-like protein. 
The device further comprise a conjugate portion down-
stream of the sample portion that includes a conjugate. The 
conjugate can be disposed on a surface of the conjugate 
portion, impregnated into the conjugate portion, or the like. 
The conjugate includes a first antibody that is selective for 
the visinin-like protein that is bound (conjugated) to a 
detection probe. The first antibody and the detection probe 
can be bound by any means, including covalent bonds, 
electrostatic, bonds, other physical interactions, and the like. 
The conjugate can be deposited along with one or more 
supporting substances. These supporting substances include, 
but are not limited to, poly (ethylene glycol) (PEG), sugars 
(i.e. dextran, maltodextrose), and surfactants, such as non-
ionic surfactants (e.g., polysorbate 20 or 80, Triton X-100). 
Supporting substances can be added for a range of purposes, 
such as to reduce non-specific interactions between the 
sample and the device, obtain desired flow velocity, and to 
control the stability, viscosity, and release of the conjugate 
material. 
The first antibody that comprises the conjugate can be of 
any class and be have dual or multiple antigen or epitope 
specificities. The first antibody can be a polyclonal antibody, 
particularly a humanized or an affinity-purified antibody 
from a human. The first antibody can be an antibody from an 
appropriate animal; e.g., a primate, goat, rabbit, mouse, or 
the like. If a paratope region is obtained from a non-human 
species, the target may be humanized to reduce immunoge-
nicity of the non-human antibodies, for use in human 
diagnostic, prognostic, or therapeutic methods. Such a 
humanized antibody or fragment thereof can also be termed 
"chimeric." For example, a chimeric antibody includes 
non-human (e.g., murine) variable regions and human con-
stant regions. Monoclonal antibodies are also suitable. A first 
antibody can include genetically engineered and/or recom-
binant proteins, whether single-chain or multiple-chain, 
which incorporate an antigen-binding site and otherwise 
function in vivo as immobilized target-binding moieties. 
12 
of polystyrene, butadiene styrenes, styreneacrylic-vinyl ter-
polymer, polymethylmethacrylate, polyethylmethacrylate, 
styrene-maleic anhydride copolymer, polyvinyl acetate, 
polyvinylpyridine, polydivinylbenzene, polybutylene-
terephthalate, acrylonitrile, vinylchloride-acrylates, and the 
like. Exemplary particles also include metallic substances, 
and in some embodiments the conjugate comprises nanogold 
beads conjugated to a first antibody that is selective for the 
visinin-like protein. 
10 The present devices further include a detection portion 
disposed along the flow path that include one or more 
immobilized targeting substances selective for the conjugate 
and/or the visinin-like protein. In some embodiments the 
15 detection portion comprises a second antibody that is selec-
tive for the visinin-like protein, and in some instances the 
first antibody and the second antibody are selective for 
different portions of the visinin-like protein. Thus, samples 
that migrate from the sample portion can remain in the 
20 detecting portion if the samples include a visinin-like protein 
that binds to the immobilized second antibody. Likewise, if 
the visinin-like protein binds to a conjugate having the 
detection probe and the first antibody, then the resulting 
complex will remain in the detecting zone when the visinin-
25 like protein binds to the second antibody. 
The detection portion can also comprise a control zone 
that includes a third targeting substance (e.g., third antibody) 
that is selective for the first antibody. As discussed above, 
the first antibody is conjugated to a detection probe. Thus, if 
30 the conjugate does not bind to a visinin-like protein, it can 
pass across the second antibody and bind to the control zone. 
Detection of the conjugate that includes the first antibody 
and the detection probe on the control zone indicates that a 
35 sample flowed through the device but contained little to no 
visinin-like protein. 
The targeting substances (e.g., second antibody and third 
antibody) can be immobilized in the detection zone as 
stripes. In this manner, a presence of the visinin-like protein 
40 can be detected if a complex including the conjugate and 
visinin-like protein bind to a location corresponding to the 
second antibody stripe. Similarly, a presence of the conju-
gate in a stripe corresponding to the control zone (e.g., third 
antibody) indicates the positive control line for the device. 
An exemplary lateral flow device is shown in FIG. 1. The 
lateral flow device in FIG. 1 comprises a sample portion (E) 
that is upstream of a conjugate portion (D), which itself 
includes nanogold labeled first antibodies that can selec-
tively bind a visinin-like protein. The nanogold labeled first 
The first antibody can be selective for a visinin-like 45 
protein. In this manner, when a sample comprising a visinin-
like protein is applied to a device, the conjugate will bind to 
the visinin-like protein via the first antibody, thereby label-
ing the visinin-like protein with the detection probe-labeled 
conjugate. The first antibody can be selective for one or 
more portions of the visinin-like protein, and in some 
embodiments is selective for the N-terminus, the C-termi-
nus, or both of a visinin-like protein. 
50 antibody/antigen complex can then migrates along a detec-
tion portion (B) that is comprised of a separation membrane. 
The complex can be trapped by a second antibody against an 
alternate portion of the visinin-like protein as a thin stripe The detection probes are not particularly limited, and 
include substances that are detectable either visually or by 55 near the termination of the separation membrane. In addition 
to rapid reaction times between the visinin-like protein and 
the first antibody, the embodied lateral flow device offers the 
advantage of inclusion of additional membranes for cell 
separation and for removal of potentially interfering proteins 
an instrumental device. Exemplary detection probes can 
include, but are not limited to, fluorescent compounds (e.g., 
fluorescent, phosphorescent, etc.), radioactive compounds, 
visual labels (e.g., colored dye or metallic substance), lipo-
somes or other vesicles containing signal-producing sub-
stances; enzymes and/or substrates, and combinations 
thereof. The detectable substance can be in the form of a 
particle, such as a nanobead. Exemplary particles include 
naturally occurring particles, such as nuclei, mycoplasma, 
plasmids, plastids, mammalian cells, unicellular microor- 65 
ganisms, polysaccharides, and the like. Exemplary particles 
can also be synthetic particles, such as particles comprised 
60 (e.g, albumin). 
EXAMPLES 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples 
set forth below. The examples may include compilations of 
data that are representative of data gathered at various times 
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during the course of development and experimentation 
related to the presently-disclosed subject matter. 
Example 1 
14 
at 60 ug/cm and dried for 1 hr at 37° C. Albumin eliminator/ 
sample portions were stored in sealed bags with desiccant at 
room temperature. 
The stored and/or treated membranes were then 
This Example describes a method for preparing a lateral 
flow device for detecting the presence of VILIP-1 in a 
biological sample. As shown in FIG. 1, the lateral flow 
device comprises of a combination of membranes that 
remove cells (e.g., whole blood) and serum albumin (e.g., rat 
5 assembled into the lateral flow device. First, a 16 mm wide 
Whatman 470 wicking portion (GE Healthcare Life Sci-
ences) was overlaid at the top of the cellulose nitrate 
membrane (detection portion) parallel to the test and control 
lines and was attached to the laminate backing. A 13 mm 
10 conjugate portion was overlaid at the bottom of the cellulose 
nitrate parallel to the test and control lines and was attached 
to laminate backing 2 mm from the bottom of the test strip. 
A 15 mm sample portion was adhered to the bottom of the 
test strip overlaying the conjugate portion. The Assembled 
or human) from a biological sample, nanogold labeled anti 
VILIP-1 raised against the N terminus of human VILIP-1, 
and a narrow line near the terminal end of anti-VILIP-1 
antibody raised against the C terminus of human VILIP-1. 
More specifically, and still referring to FIG. 1, the lateral 
flow device comprised a laminate backing (A; MIBA-010; 
Diagnostic Consulting Network, Carlsbad, Calif.), a sample 
portion for receiving a biological sample (E; Vivid Plasma 
Separation-GX; Pall Corporation, Port Washington, N.Y.), a 20 
conjugate portion (D; Pall, Grade 896), a detection portion 
(B; Unisart CN140 Nitrocellulose Membrane, 42 mm; Sar-
torius Stedin North America Inc, Bohemia, N.Y.), and a 
wicking portion (C; Whatman 470; GE Healthcare Life 
Sciences, Piscataway, N.J.). 
15 membranes were cut into 4 mm wide strips and fitted into 
MICA-010 2-hole cassettes (Diagnostic Consulting Net-
work, Carlsbad, Calif.) assemblies. Assembled lateral flow 
devices were stored in sealed sample bags with desiccant at 
room temperature for future use. 
Example 2 
This Example describes procedures conducted to evaluate 
how the embodiments of lateral flow devices that were 
25 prepared in Example 1 can be used to detect the presence of 
VILIP-1 in subjects having brain damage, including brain 
damage caused by ischemic stroke or TBI. 
To prepare the antibodies, all antibodies were dialyzed 
against water overnight at 4° C., lyophilized, and re-sus-
pended in lx PBS (pH 7.4) at concentrations described in 
this Example. Next, monoclonal VILIP-1 PL-A2 (Abnova, 
Taipei City, Neihu District, Taiwan) at a concentration of 2 30 
mg/mL was conjugated to 40 nm go! sol per manufacturers' 
instructions (BioAssay Works, Fredrick, Md., USA) with 
modification. Briefly 6 flg of VILIP-1 PL-A2 was conju-
gated with 0.5 mL of 40 nm Naked Gold Sol (OD 7.5) for 
First, using recombinant VILIP-1 as a standard protein, a 
limit of detection of 0.2 ng/ml serum and a linear response 
between 0.2 ng/ml and 7.0 ng/ml was detected (r=0.91). 
FIG. 2 shows levels ofVILIP-1 in normal control serum are 
below the limit of detection. Thus, the lateral flow devices 
were capable of detecting the presence of VILIP-1 in bio-
logical samples. 
To determine if serum VILIP-1 levels change in due to 
ischemic stroke, animals were subjected to a 1 hour middle 
cerebral artery occlusion (MCAO) using the Zea Longa 
method. Specifically, nine three-month-old Sprague-Dawley 
rats (250-300 g) were subjected to a 1 hour ischemic event 
5 min at room temperature with constant gentle agitation. 35 
Conjugation was stopped by the addition of 10% BSA 
solution for 1 hr at room temperature with constant agitation 
followed by the treatment with N-ethylmalemide at a final 
concentration of 20 nM for 1 hr at room temperature with 
constant agitation. 40 induced by suture occlusion of the middle cerebra artery. 
The antibody-nanogold conjugate was then added to the 
conjugate portion. Specifically, the mouse anti-VILIP-1 
PL-A2/nanogold conjugate was mixed with 25% sucrose/ 
1% Tween 20 in PBS and Rabbit anti-goat IgG Dressed Gold 
(BioAssay Works) in a 1:0.6:1.7 ratio and applied to 25% 45 
sucrose/!% Tween 20 in PBS pre-coated at 10 uL/cm Pall 
Grade 8964 conjugate portion (Pall, Port Washington, N.Y., 
USA) using an Air-Jet sprayer (BioDot, Irvine, Calif., USA) 
Control animals (N=5) were subjected to surgical prepara-
tion but without occlusion. Blood samples (50 f.LL) were 
obtained from the left femoral artery prior to occlusion, 
when the occlude was removed (pre-reperfusion), 15 min-
utes after initiation of reperfusion, and 24 hour post reper-
fusion. 
To examine serum levels ofVILIP-1 in TBI, four 3 month 
old Sprague-Dawley rats were subjected to mild or moderate 
controlled cortical impact (CCI) or sham surgery in which a at a volume of 70 uL/cm and dried for 1 hr at 37° C. 
Conjugate portions were stored in sealed sample bags with 
desiccant at room temperature. 
Next, the Unistart CN140 cellulase nitrate membranes 
(detection portion) were applied to the MIBA-010 laminate 
backing Rabbit anti-VILIP-1 K-25 (Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif.) at a final concentration of 0.5 
mg/mL and Goat Serum (Invitrogen, Carlsbad, Calif.,) were 
applied in parallel stripes using Bio-Jet equipment (BioDot) 
at 4 ug/cm and 16 uL/cm and 30 and 37 mm from the bottom 
of the lateral flow device, respectively. The membranes were 
dried for 1 hr at 3 7° C. blocked in 1% dry milk/PBS for 15 
minutes, washed 3 times in PBS, and dried for 1 hr at 37° C. 
Backed cellulose nitrate membranes were stored in sealed 
sample bags with desiccant at room temperature. 
Sheep anti-rat (Bethyl Laboratories, Montgomery, Tex., 
USA; 4 mg/mL) or anti-human albumin (Santa Cruz) was 
then applied to the Vivid Plasma Separation-GX (Pall Cor-
poration) sample portions using a Bio-Jet sprayer (BioDot) 
50 portion of the skull was removed but without brain impact. 
Control rats consisted of surgery naive rates (N=4) anesthe-
tized but without any surgical manipulation. For analyses, 
whole blood (100-200 f.LL) samples were taken prior to 
beginning surgeries and 1, 2, and 3 hour post injury from tail 
55 nicks of the young adult male Spraque-Dawley rats under 
isoflurane anesthesia (2% ). 
Immediately following collection, whole blood (1 0 f.LL) or 
serum (10 f.LL) samples were applied to the asymmetric 
sample portion, resulting in the removal of red blood cells 
60 from the sample. Three minutes post sample loading 20 f.LL 
of lateral flow device sample buffer (0.5% Surfactant 1 OG, 
0.8 USP heparin/mL) was applied directly to the conjugate 
portion to prevent lysis of red blood cells trapped in the 
asymmetrical sample portion and facilitate migration of the 
65 sample through the cellulose nitrate membrane. The test and 
control lines were observed for color development at 15 
minutes post-sample loading, and images were captured for 
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with hemorrhagic stroke and two subjects with ischemic 
stroke and showed mean±SD concentrations of 
1988.7±714.4 ng/ml for the ischemic stroke patients and 
7125.8±1254.1 ng/ml for subjects with hemorrhagic stroke. 
The measured values were positively related to infarct 
volume measured by MRI (FIG. 9). 
analysis. Gold Enhance LM/Blot (Nanoprobes, Yaphank, 
N.Y., USA) was prepared per manufacturer's directions and 
20 f.LL was applied directly to the lateral flow device mem-
branes. Color development was observed 15 minutes post-
color enhancement and images were taken for analysis. The 
remaining whole blood samples were centrifuged at 
15,000xg for 5 minutes and the serum samples were col-
lected and stored at -80° C. for later analysis. 
Example 3 
It will be understood that various details of the presently 
disclosed subject matter can be changed without departing 
from the scope of the subject matter disclosed herein. 
10 
Furthermore, the description provided herein is for the 
purpose of illustration only, and not for the purpose of 
limitation. 
This Example describes the relationship between VILIP-1 
levels and brain damage that were observed using the 
procedures described in Example 2. Specifically, this 
Example describes how VILIP-1 levels were affected by the 
induced ischemic stroke and TBI in rat subjects. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth herein to facilitate explanation of the presently-
15 disclosed subject matter. 
As described above, whole blood (10 f.LL) were analyzed 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
at the time of draw and the remaining blood samples were 
centrifuged to prepare serum which was analyzed from all 
time points later. FIG. 3 shows that levels of VILIP-1 in 
serum were considerably higher in mild TBI compared to 
ischemic stroke 1 hour and 15 minutes post injury, thereby 
suggesting that TBI can induce more pronounced neuronal 
injury (i.e., brain damage). Without being bound by theory 
or mechanism, VILIP-1 levels for subjects having experi-
enced hemorrhagic stroke can be comparable to those 
observed in TBI because hemorrhagic stroke can cause 
severe tissue damage. Thus, optionally when combined with 
clinical presentation, the presence of VILIP-1, including at 
concentrations below a level corresponding to TBI or hem-
orrhagic stroke, can provide a delineation of ischemic stroke 
from hemorrhagic stroke. 
20 methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are described herein. 
The terms "comprising", "including," and "having" are 
25 intended to be inclusive and mean that there may be addi-
tional elements other than the listed elements. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a protein" includes a plurality of such proteins, and 
30 
so forth. 
With regard to the rats having the induced ischemic 
stroke, FIG. 4 shows serum levels of VILIP-1 increased 
significantly immediately after the occlude was removed. 35 
FIG. 4 also suggests that serum levels ofVILIP-1 reached a 
maximum after initiation of reperfusion, and remained 
elevated 24 hours post injury. Correlation analyses showed 
VILIP-1 levels were significantly correlated (r=0.61) with 
lesion volume measured 24 hour post-injury. FIG. 5 shows 40 
receiver operating characteristic (ROC) curves for VILIP-1 
levels at each time point and shows sensitivity/specificity 
values of 89 and 75% with an area under the curve (AUC) 
of 86% for 15 minutes post reperfusion and 100% sensitiv-
ity/75% specificity and an AUC=97% for 24 hours post 45 
reperfusion. 
For the rats subjected to TBI, FIG. 6 shows mean±SEM 
serum VILIP-1 levels, and shows that VILIP-1 levels in 
serum progressively increased 1 hour, 3 hours, and 4 hours 
post injury for both mild TBI and moderate TBI test groups. 50 
FIG. 7 shows ROC for VILIP-1 in the subjects having mold 
TBI and moderate TBI. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1% from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
Example 4 
This Example describes a diagnostic procedure conducted 
on human samples using the methods and device described 
in Examples 1 and 2. 
two particular units are also disclosed. For example, if 10 
55 and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
Serum samples from a commercial source that were taken 
from patients 6 hours after ischemic (N=2) or hemorrhagic 60 
(N=2) stroke. Serum samples (10 fll) were applied to LFDs 
as described above, and intensity of the trapped nanogold 
was quantified using Scion Image Analysis. Quantification 
of VILIP-1 levels was carried out using a calibration curve 
constructed using increasing concentrations of standard 65 
VILIP-1 prepared in 70% control serum. FIG. 8 shows 
results of the analysis of serum samples from two subjects 
Throughout this document, various references are men-
tioned. Such references include, but are not limited to, 
publications, patents, and patent applications. All such ref-
erences are incorporated herein by reference, including the 
references set forth in the following list: 
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ing a second antibody selective for a C-terminal portion 
of VILIP-1 immobilized thereon, wherein the second 
anti-VI LIP -1 antibody captures the first antibody and 
VILIP-1 complex resulting in detectable signals indica-
tive of the presence and/or amount of the VILIP-1 
protein in the biological sample. 
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13. The method of claim 12, wherein the detectable 
signals occur within a period of time less than 15 minutes 
from providing the biological sample to the separation 
10 membrane. 
14. The method of claim 12, wherein the biological 
sample is a blood sample, a serum sample, or a plasma 
sample. 
115. Dubal, D. B., eta!., Estradiol protects against ischemic 
injury. J Cereb Blood Flow Metab, 1998. 18(11): p. 
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What is claimed is: 
1. A lateral flow device for detecting a presence of 15 
VILIP-1 protein in a biological sample, comprising: 
a sample portion for receiving the biological sample, 
wherein the sample portion removes red blood cells-
a conjugate portion downstream of the sample portion th~t 
includes a conjugate, the conjugate including a first 20 
antibody conjugated to a detection probe, wherein the 
first antibody is selective for a first portion ofVILIP-1, 
wherein the first portion is not a C-terminal portion of 
VILIP-1; and, 
a detection portion downstream of the conjugate portion 25 
that includes a second antibody that is selective for a 
second portion ofVILIP-1, wherein the second portion 
15. The method of claim 12, wherein the biological 
sample is 10 fll or less in volume. 
16. The method of claim 12, wherein the sample portion 
comprises a material for removing red blood cells selected 
from the group consisting of: asymmetric polysulfone, glass 
fiber filter, or unsaturated aliphatic fatty acid or ester thereof. 
17. The method of claim 12, wherein the biological 
sample is obtained from a subject suspected of suffering a 
brain injury or trauma. 
18. The method of claim 17, wherein the biological 
sample is obtained from the subject within 60 minutes after 
suspected brain injury or trauma. 
19. The method of claim 17, wherein the brain injury or 
trauma is neuronal damage, hypoxic damage or combina-
tions thereof. is a C-terminal portion of VILIP-1. 
2. The device of claim 1, wherein the sample portion 
further comprises a buffer solution. 
20. The method of claim 17, wherein the subject is a 
30 premature infant. 
21. The method of claim 17, wherein the brain injury or 
trauma is stroke. 
3. The device of claim 1, wherein the detection probe is 
selected from a fluorescent compound, radioactive com-
pound, a visual label, nanobeads and combinations thereof. 
4. The device of claim 1, wherein the sample portion 
comprises a material for removing red blood cells selected 35 
from the group consisting of: asymmetric polysulfone, glass 
fiber filter, or unsaturated aliphatic fatty acid or ester thereof. 
5. The device of claim 3, wherein the nanobeads are 
nanogold beads. 
22. The method of claim 21, wherein the stroke is 
hemorrhagic or ischemic. 
23. The method of claim 17, wherein the brain injury or 
trauma is traumatic brain injury (TBI). 
24. The method of claim 23, wherein based on the 
concentration of VILIP-1 protein the TBI can be diagnosed 
as mild, medium or severe. 
25. The method of claim 12, wherein the concentration of 
the VILIP-1 protein in the biological sample is less than 500 
ng/ml. 
6. The device of claim 1, wherein the detection zone 40 
further comprises a control zone comprising a third antibody 
selective for the first antibody. 
26. The method of claim 12, wherein the detection probe 
may be selected from the group comprising fluorescent 
45 compounds, radioactive compounds, nanobeads, visual 
labels, or combinations thereof. 
7. The device of claim 1, wherein the second or third 
antibody are immobilized in the detection zone as a stripe at 
a concentration of 4 f.tg/cm. 
8. The device of claim 1, wherein the antibodies of the 
conjugate zone are immobilized on a conjugate pad. 
9. The device of claim 1, wherein the detection zone 
comprises a nitrocellulose membrane. 
10. The device of claim 1, further comprising a wicking 50 
portion. 
11. The device of claim 1, wherein the first anti-VILIP-1 
antibody associated with a detection probe is deposited with 
one or more supporting substances. 
12. A method of detecting VILIP-1 protein in a biological 55 
sample, comprising 
27. The method of claim 26, wherein the nanobeads are 
nanogold beads. 
28. The device of claim 1, wherein one or both of the first 
portion and the second portion is or comprises a conforma-
tion of VILIP-1. 
29. The device of claim 1, wherein the first portion is that 
recognized by antibody PL-A2 and/or the second portion is 
that recognized by antibody K-25. 
30. The device of claim 1, wherein the first antibody is or 
comprises PL-A2 and or wherein the second antibody is or 
comprises K-25. 
31. The method of claim 12, wherein one or both of the 
first portion and the second portion is or comprises a 
conformation of VILIP-1. 
32. The method of claim 12, wherein the first portion is 
that recognized by antibody PL-A2 and/or the second por-
tion is that recognized by antibody K-25. 
providing a biological sample to a sample portion 
upstream of a conjugation zone of a separation mem-
brane, wherein the sample portion removes red blood 
cells from the biological sample and wherein the con- 60 
jugation zone comprises a first antibody selective for a 
non C-terminal portion of VILIP-1 associated with a 
detection probe immobilized thereon such that the 
VILIP-1 protein, if present in the biological sample, 
form a first antibody and VILIP-1 complex; and 
33. The method of claim 12, wherein the first antibody is 
65 or comprises PL-A2 and or wherein the second antibody is 
or comprises K-25. migrating the first antibody and VILIP-1 complex along 
the separation membrane to a detection zone compris-
* * * * * 
